We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Realigning interests.
- Abstract
The author contends that multiple interests have to be aligned for the commercial sector to have more incentive to develop novel therapies in the U.S. in March 2011. He says that the investment, regulatory and reimbursement regimes governing the sector actively discourage industry from adopting innovation. He adds that the government can intervene and realign market incentives so that companies and investors can embrace the needed high risk in developing the medicines of tomorrow. He also discusses the improved funding for translational research.
- Subjects
UNITED States; THERAPEUTICS; BIOTECHNOLOGY; MEDICINE
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 3, p171
- ISSN
1087-0156
- Publication type
Editorial
- DOI
10.1038/nbt.1829